Johnson & Johnson Vaccine 66 Percent Effective

A COVID-19 single-shot vaccine from Johnson & Johnson was 66 percent effective in preventing moderate or severe disease in a Phase 3 clinical trial, a level of protection above the Food and Drug Administration’s minimum, but lower than authorized Pfizer and Moderna vaccines.

There is also a warning sign from the variant found in South Africa. The efficacy dropped from 72 percent in the United States, to 57 percent in South Africa, where a new coronavirus variant is prevalent.

That new variant has responded less well to a range of vaccines, including now this one, causing concern among experts. Still, a range of vaccines are still thought to provide protection against the variant.

The company plans to file for authorization from the FDA in “early February,” meaning the vaccine could soon add to the U.S. arsenal against the vaccine.

Read more at The Hill.

{Matzav.com}